BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C.auris - Touching Base | Lyssna här

Bristol Myers Squibb has selected Houston as the site for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods manufacturing from late development through launch. Recursion, Roche, and its Genentech subsidiary have announced plans to co-develop a neuroscience discovery program based on the first validated target discovered through an AI map. Editors reminisce over the changes in science since the COVID-19 pandemic in light of a new large NIH-funded study that shows COVID-19 can reactivate dormant viruses, including Epstein-Barr and cytomegalovirus. In other infectious disease news, drug-resistant Candida auris was found to persist in hair follicles by exposing chitin, triggering interferon-γ that suppresses skin defenses and creates a niche for fungal colonization.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Julianna LeMieux, PhD, for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base: 

BMS Chooses Houston for $2.3B Manufacturing Facility

By Alex Philippidis, GEN Edge, Aug 10, 2026

Next 10 U.S. Biopharma Clusters

By Alex Philippidis, GEN, Aug 12, 2026

Recursion Partners with Genentech to Advance First Validated Neuro Target Discovered Through AI Map

By Alex Philippidis, GEN Edge, Aug 5, 2026

COVID-19 Reactivates Dormant Viruses, Offering New Clues to Long COVID

GEN, Aug 5, 2026

Trump’s Treatments: Regeneron’s Antibodies and Gilead’s Remdesivir Explained

By Alex Philippidis, GEN, Oct 5, 2020